FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953392779> ?p ?o ?g. }

• W2953392779 endingPage "1052" @default.
• W2953392779 startingPage "1036" @default.
• W2953392779 abstract "Targeting the CD47-signal-regulatory protein α (SIRPα) pathway represents a novel therapeutic approach to enhance anti-cancer immunity by promoting both innate and adaptive immune responses. Unlike CD47, which is expressed ubiquitously, SIRPα expression is mainly restricted to myeloid cells and neurons. Therefore, compared to CD47-targeted therapies, targeting SIRPα may result in differential safety and efficacy profiles, potentially enabling lower effective doses and improved pharmacokinetics and pharmacodynamics. The development of effective SIRPα antagonists is restricted by polymorphisms within the CD47-binding domain of SIRPα, necessitating pan-allele reactive anti-SIRPα antibodies for therapeutic intervention in diverse patient populations. We immunized wild-type and human antibody transgenic chickens with a multi-allele and multi-species SIRPα regimen in order to discover pan-allelic and pan-mammalian reactive anti-SIRPα antibodies suitable for clinical translation. A total of 200 antibodies were isolated and screened for SIRPα reactivity from which approximately 70 antibodies with diverse SIRPα binding profiles, sequence families, and epitopes were selected for further characterization. A subset of anti-SIRPα antibodies bound to both human SIRPα v1 and v2 alleles with high affinity ranging from low nanomolar to picomolar, potently antagonized the CD47/SIRPα interaction, and potentiated macrophage-mediated antibody-dependent cellular phagocytosis in vitro. X-ray crystal structures of five anti-SIRPα antigen-binding fragments, each with unique epitopes, in complex with SIRPα (PDB codes 6NMV, 6NMU, 6NMT, 6NMS, and 6NMR) are reported. Furthermore, some of the anti-SIRPα antibodies cross-react with cynomolgus SIRPα and various mouse SIRPα alleles (BALB/c, NOD, BL/6), which can facilitate preclinical to clinical development. These properties provide an attractive rationale to advance the development of these anti-SIRPα antibodies as a novel therapy for advanced malignancies. Abbreviations: ADCC: antibody-dependent cellular cytotoxicity; ADCP: antibody-dependent cellular phagocytosis; CFSE: carboxyfluorescein succinimidyl ester; Fab: fragment antigen binding; Fc: fragment crystallizable; FcγR: Fcγ receptor; Ig: immunoglobulin; IND: investigational new drug; MDM⊘: monocyte-derived macrophage; NOD: non-obese diabetic; scFv: single chain fragment variable; SCID: severe combined immunodeficiency; SIRP: signal-regulatory protein." @default.
• W2953392779 created "2019-07-12" @default.
• W2953392779 creator A5000341676 @default.
• W2953392779 creator A5005298033 @default.
• W2953392779 creator A5005301498 @default.
• W2953392779 creator A5006757467 @default.
• W2953392779 creator A5012221363 @default.
• W2953392779 creator A5019722127 @default.
• W2953392779 creator A5032366346 @default.
• W2953392779 creator A5034421347 @default.
• W2953392779 creator A5075240281 @default.
• W2953392779 creator A5075953198 @default.
• W2953392779 creator A5078247882 @default.
• W2953392779 creator A5080281814 @default.
• W2953392779 creator A5082270484 @default.
• W2953392779 creator A5083141467 @default.
• W2953392779 creator A5083145299 @default.
• W2953392779 creator A5089392343 @default.
• W2953392779 date "2019-07-01" @default.
• W2953392779 modified "2023-10-09" @default.
• W2953392779 title "Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα" @default.
• W2953392779 cites W1529809181 @default.
• W2953392779 cites W1912672559 @default.
• W2953392779 cites W1946393286 @default.
• W2953392779 cites W1966217032 @default.
• W2953392779 cites W1966693080 @default.
• W2953392779 cites W1981878585 @default.
• W2953392779 cites W1990759477 @default.
• W2953392779 cites W1992714434 @default.
• W2953392779 cites W1997065981 @default.
• W2953392779 cites W1997254819 @default.
• W2953392779 cites W2000310558 @default.
• W2953392779 cites W2001900040 @default.
• W2953392779 cites W2019637120 @default.
• W2953392779 cites W2033577259 @default.
• W2953392779 cites W2040446474 @default.
• W2953392779 cites W2057796048 @default.
• W2953392779 cites W2068052762 @default.
• W2953392779 cites W2072750828 @default.
• W2953392779 cites W209560489 @default.
• W2953392779 cites W2097733789 @default.
• W2953392779 cites W2103339246 @default.
• W2953392779 cites W2106545303 @default.
• W2953392779 cites W2106744501 @default.
• W2953392779 cites W2109860639 @default.
• W2953392779 cites W2133346943 @default.
• W2953392779 cites W2136164578 @default.
• W2953392779 cites W2139418176 @default.
• W2953392779 cites W2141253335 @default.
• W2953392779 cites W2205886515 @default.
• W2953392779 cites W2337675328 @default.
• W2953392779 cites W2339658610 @default.
• W2953392779 cites W2413927991 @default.
• W2953392779 cites W2474091620 @default.
• W2953392779 cites W2568765466 @default.
• W2953392779 cites W2578585563 @default.
• W2953392779 cites W2592953803 @default.
• W2953392779 cites W2594014934 @default.
• W2953392779 cites W2599261484 @default.
• W2953392779 cites W2753470570 @default.
• W2953392779 cites W2754767805 @default.
• W2953392779 cites W2758186654 @default.
• W2953392779 cites W2765122284 @default.
• W2953392779 cites W2770192040 @default.
• W2953392779 cites W2791483720 @default.
• W2953392779 cites W2793275933 @default.
• W2953392779 cites W2888609501 @default.
• W2953392779 cites W2899044337 @default.
• W2953392779 cites W4231314059 @default.
• W2953392779 cites W4234185730 @default.
• W2953392779 cites W4238480525 @default.
• W2953392779 doi "https://doi.org/10.1080/19420862.2019.1624123" @default.
• W2953392779 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6748616" @default.
• W2953392779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31257988" @default.
• W2953392779 hasPublicationYear "2019" @default.
• W2953392779 type Work @default.
• W2953392779 sameAs 2953392779 @default.
• W2953392779 citedByCount "34" @default.
• W2953392779 countsByYear W29533927792020 @default.
• W2953392779 countsByYear W29533927792021 @default.
• W2953392779 countsByYear W29533927792022 @default.
• W2953392779 countsByYear W29533927792023 @default.
• W2953392779 crossrefType "journal-article" @default.
• W2953392779 hasAuthorship W2953392779A5000341676 @default.
• W2953392779 hasAuthorship W2953392779A5005298033 @default.
• W2953392779 hasAuthorship W2953392779A5005301498 @default.
• W2953392779 hasAuthorship W2953392779A5006757467 @default.
• W2953392779 hasAuthorship W2953392779A5012221363 @default.
• W2953392779 hasAuthorship W2953392779A5019722127 @default.
• W2953392779 hasAuthorship W2953392779A5032366346 @default.
• W2953392779 hasAuthorship W2953392779A5034421347 @default.
• W2953392779 hasAuthorship W2953392779A5075240281 @default.
• W2953392779 hasAuthorship W2953392779A5075953198 @default.
• W2953392779 hasAuthorship W2953392779A5078247882 @default.
• W2953392779 hasAuthorship W2953392779A5080281814 @default.
• W2953392779 hasAuthorship W2953392779A5082270484 @default.
• W2953392779 hasAuthorship W2953392779A5083141467 @default.
• W2953392779 hasAuthorship W2953392779A5083145299 @default.

• next